Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Regeneron Pharmaceuticals
Duration per participant was up to 28 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants, male or female 18 years or older,
with diagnosed chronic AD, demonstrated 1) inadequate response to topical medications, 2) expected severity of AD and 3) sleep disturbance.
had applied skin emollients (moisturizers) at least 7 days before screening.
had applied medium potency topical corticosteroids (TCS) on all active AD lesions at least 7 days before screening.
willed and able to comply with all clinic visits and study-related procedures.
provided signed informed consent.
You may not be if
Participants excluded from the study:
with known hypersensitivity to Dupixent, clinical depression, drug abuse history, sleep problems not related to AD, irregular sleep pattern, active/acute infections, severe medical conditions, laboratory abnormalities, any condition that might present unreasonable risk to participants or interfered with study assessment, or any severe concomitant illness(es) that would adversely affect the participant's participation in the study, and contraindications of topical corticosteroids.
at Baseline, presence of any conditions listed as criteria for study drug discontinuation.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Clareo Health | SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
